이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

선택적 골수증식종양을 가진 참가자를 대상으로 한 PRT12396의 1상 연구

2026년 10월 28일 업데이트: Prelude Therapeutics Incorporated

PRT12396의 진성적혈구증가증 및 골수섬유증 환자를 대상으로 한 1상, 개방형, 다기관, 안전성 및 유효성 연구

This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]). The study consists of a dose-escalation phase followed by a dose-expansion phase to further evaluate selected dose level(s).

연구 개요

상세 설명

This first-in-human, open-label, multi-center Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF). Eligible MF populations include participants with intermediate-1, intermediate-2, or high-risk primary MF, as well as post-polycythemia vera MF or post-essential thrombocythemia MF, with evidence of disease burden based on splenomegaly.

The study is conducted in two parts:

Part 1 (dose escalation) evaluates escalating oral doses of PRT12396 to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]).

Part 2 (dose expansion) enrolls additional participants at selected dose level(s) to further characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in the PV and MF populations.

Approximately up to 100 participants are planned for enrollment across both parts of the study.

연구 유형

중재적

등록 (추정된)

100

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • California
      • Los Angeles, California, 미국, 90095
        • 모병
        • UCLA Ronald Reagan Medical Center
      • Sacramento, California, 미국, 95817
        • 모병
        • University of California, Davis Comprehensive Cancer Center
    • Colorado
      • Denver, Colorado, 미국, 80218
        • 모병
        • Colorado Blood Cancer Institute
    • Florida
      • Coral Springs, Florida, 미국, 33065
        • 모병
        • BRCR Global - Coral Springs
      • Miami, Florida, 미국, 33136
        • 모병
        • Sylvester Comprehensive Cancer Center
      • Tampa, Florida, 미국, 33612
        • 모병
        • Moffitt Cancer Center
    • Michigan
      • Grand Rapids, Michigan, 미국, 49546
        • 모병
        • START Midwest, LLC
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19107
        • 모병
        • Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office
    • Tennessee
      • Nashville, Tennessee, 미국, 37203
        • 모병
        • Tristar BMT
      • Nashville, Tennessee, 미국, 37203
        • 모병
        • Tennessee Oncology, PLLC - Investigational Drug Services
    • Texas
      • Houston, Texas, 미국, 77030
        • 모병
        • The University of Texas, MD Anderson Cancer Center
      • Barcelona, 스페인, 08036
        • 모병
        • Hospital Clinic de Barcelona
      • Madrid, 스페인, 28034
        • 모병
        • Hospital Universitario Ramon y Cajal
      • Madrid, 스페인, 28041
        • 모병
        • Hospital Universitario 12 de Octubre
      • Valencia, 스페인, 46010
        • 모병
        • Hospital Clínico Universitario de Valencia
      • Florence, 이탈리아, 50134
        • 모병
        • Azienda Ospedaliero Universitaria Careggi
      • Nice, 프랑스, 06200
        • 모병
        • Nice University Medicâl Center (CHU Nice, Hôpital Archet 1)
      • Paris, 프랑스, 75010
        • 모병
        • Saint-Louis Hospital
      • Toulouse, 프랑스, 31059
        • 모병
        • Oncopole Claudius Regaud
    • South Australia
      • Adelaide, South Australia, 호주, 5000
        • 모병
        • Royal Adelaide Hospital
    • Victoria
      • Clayton, Victoria, 호주, 3168
        • 모병
        • Monash Health, Monash Medical Centre
    • Western Australia
      • Nedlands, Western Australia, 호주, 6009
        • 모병
        • One Clinical Research

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations (including contraception requirements), and other study procedures.
  • Confirmed diagnosis of PV or MF according to WHO 2016 or revised ICC/WHO 2022 criteria
  • Documented presence of a JAK2 V617 mutation
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Estimate life expectancy of ≥12 weeks per investigator assessment.
  • Negative serum or urine pregnancy test and agree to use contraception or maintain true abstinence.
  • Adequate organ function and bone marrow reserves (hematology, renal, and hepatic)

Exclusion Criteria:

  • History of another malignancy within 3 years prior to enrollment, except for malignancy considered cured with low risk of recurrence.
  • Clinically significant anemia due to nutritional deficiency or hemolytic disorders.
  • Active or uncontrolled infection requiring systemic therapy or hospitalization.
  • Any other medical or psychiatric conditions that, in the Investigator's judgment, would increase risk or interfere with study participation or interpretation of results.
  • Clinically significant or uncontrolled medical conditions, including active infection or cardiovascular disease, that would increase risk or interfere with study participation.
  • Unresolved toxicity Grade >1 from prior anticancer therapy, except for alopecia or peripheral neuropathy Grade ≤2.
  • Pregnancy or breastfeeding
  • Known sensitivity or contraindication to any component of study, or the excipients of study treatment.
  • Prior systemic therapy for PV or MF, prior or planned allogeneic hematopoietic stem-cell transplantation, recent major surgery, prior splenectomy or prior splenic irradiation, or use of hematopoietic growth factors within protocol-defined washout periods.
  • Use of strong or moderate cytochrome P450 (CYP) 3A4 inhibitor or inducer, sensitive CYP3A substrates with narrow therapeutic range, or acid-reducing agents that cannot be discontinued prior to study treatment.
  • Participation in another interventional clinical study.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: PRT12396: MF

Participants with myelofibrosis receive PRT12396, an investigational oral capsule, administered twice daily. The study includes a dose-escalation followed by dose-expansion at the recommended dose for expansion (RDE)

PRT12396 is an investigational oral capsule administered twice daily at the assigned dose level or RDE. Capsules are swallowed whole with water and may be taken one hour before or two hours after meals.

실험적: PRT12396: PV

Participants with polycythemia vera receive PRT12396, an investigational oral capsule, administered twice daily. The study includes a dose-escalation followed by dose-expansion at the recommended dose for expansion (RDE)

PRT12396 is an investigational oral capsule administered twice daily at the assigned dose level or RDE. Capsules are swallowed whole with water and may be taken one hour before or two hours after meals.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Dose limiting toxicity (DLT) of PRT12396
기간: Through cycle 1 (4 weeks)

Incidence of dose limiting toxicities, defined according to protocol-specified criteria

Through cycle 1 (4 weeks)
Incidence and severity of Adverse events
기간: Through study completion, an average of 2 years

Incidence and severity of treatment-emergent adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 6.0

Through study completion, an average of 2 years
Adverse Events Leading to Dose Modifications or Discontinuation
기간: Through study completion, an average of 2 years

Incidence of AEs leading to dose reductions, dose interruptions, treatment discontinuations, and clinically significant laboratory abnormalities

Through study completion, an average of 2 years
Maximum tolerated dose (MTD) and Recommended Dose(s) for Expansion (RDE[s]) of PRT12396
기간: Through study completion, an average of 2 years

Determination of the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]) based on evaluation of DLTs, safety, and tolerability data

Through study completion, an average of 2 years

2차 결과 측정

결과 측정
측정값 설명
기간
Hematologic Response Rate (PV)
기간: Through study completion, an average of 2 years

Proportion of participants with polycythemia vera (PV) achieving best overall hematologic response (complete hematologic response or partial hematologic response) from the overall response assessments by Investigator

Through study completion, an average of 2 years
Duration of Hematologic Response (PV)
기간: Through study completion, an average of 2 years

Duration of hematologic response in PV participants, defined as the time from first documented response (best overall hematologic response) to disease progression or death, whichever comes first

Through study completion, an average of 2 years
Hematocrit Control Without Phlebotomy Requirements (PV)
기간: Through study completion, an average of 2 years

Proportion of PV participants achieving and maintaining hematocrit control without phlebotomy, time to first phlebotomy, and frequency of phlebotomy

Through study completion, an average of 2 years
Spleen Response (MF)
기간: Through study completion, an average of 2 years

Assessment of spleen response including proportion achieving protocol-specified reduction in spleen volume, time to spleen response, duration of spleen response, and reduction in palpable spleen length

Through study completion, an average of 2 years
Change from Baseline in Hemoglobin (MF)
기간: Through study completion, an average of 2 years

Change from baseline in hemoglobin levels in MF participants

Through study completion, an average of 2 years
Change from Baseline in Platelet Count (MF)
기간: Through study completion, an average of 2 years

Change from baseline in platelet count in MF participants

Through study completion, an average of 2 years
Change from Baseline in Absolute Neutrophil Count (MF)
기간: Through study completion, an average of 2 years

Change from baseline in absolute neutrophil count in MF participants

Through study completion, an average of 2 years
Transfusion Independence (MF)
기간: Through study completion, an average of 2 years

Proportion achieving transfusion independence and duration of transfusion independence as defined by protocol criteria

Through study completion, an average of 2 years
Maximum Observed Plasma Concentration (Cmax)
기간: Up to Cycle 4 Day 1 (each cycle is 4 weeks)

Maximum observed plasma concentration will be calculated using non-compartmental analysis

Up to Cycle 4 Day 1 (each cycle is 4 weeks)
Time To Maximum Concentration (Tmax)
기간: Up to Cycle 4 Day 1 (each cycle is 4 weeks)

Time to maximum concentration will be calculated using non-compartmental analysis

Up to Cycle 4 Day 1 (each cycle is 4 weeks)
Area under the plasma concentration versus time curve (AUC)
기간: Up to Cycle 4 Day 1 (each cycle is 4 weeks)

Area under the plasma concentration-time curve will be calculated using non-compartmental analysis

Up to Cycle 4 Day 1 (each cycle is 4 weeks)
Terminal Elimination Half-life (T1/2)
기간: Cycle 1 Day 1

Terminal elimination half-life will be calculated using non-compartmental analysis

Cycle 1 Day 1
Steady State Trough Concentrations
기간: Up to Cycle 4 Day 1 (each cycle is 4 weeks)

Steady state trough concentrations will be calculated using non-compartmental analysis

Up to Cycle 4 Day 1 (each cycle is 4 weeks)
Clearance
기간: Cycle 1 Day 1

Clearance will be calculated using non-compartmental analysis

Cycle 1 Day 1
Accumulation
기간: Up to Cycle 4 Day 1 (each cycle is 4 weeks)

Accumulation will be calculated using non-compartmental analysis

Up to Cycle 4 Day 1 (each cycle is 4 weeks)
Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)
기간: Through study completion, an average of 2 years

Patient-reported outcomes assessed using the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS), evaluated as change from baseline at protocol-specified time points. The MPN SAF TSS is a validated questionnaire in which individual symptoms are scored using a numeric rating scale ranging from 0 to 10, with 0 indicating no symptoms and 10 indicating the worst imaginable symptoms; higher scores indicate greater symptom severity.

Through study completion, an average of 2 years
Patient Global Impression of Change (PGI-C)
기간: Through study completion, an average of 2 years

Participant reported outcomes assessed using the Patient Global Impression of Change (PGI-C), evaluated at protocol-specified time points. The PGI C is a global assessment scale in which participants rate their overall change in condition since baseline using a 7 point ordinal scale ranging from "very much improved" to "very much worse," with lower scores indicating improvement and higher scores indicating worsening of symptoms.

Through study completion, an average of 2 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 4월 29일

기본 완료 (추정된)

2028년 4월 1일

연구 완료 (추정된)

2028년 4월 1일

연구 등록 날짜

최초 제출

2026년 2월 26일

QC 기준을 충족하는 최초 제출

2026년 3월 9일

처음 게시됨 (실제)

2026년 3월 13일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 29일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 28일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다